Remove 2008 Remove Metabolic Stability Remove Trials
article thumbnail

How the AI revolution can accelerate early drug discovery

Drug Target Review

How AI/ML technology has accelerated drug discovery Although AI for drug discovery (AIDD) can be viewed as being in the initial phases of development and acceptance, compounds discovered using AIDD platforms are already entering clinical trials. To really benefit from AI, the pharmaceutical industry must be more open to data sharing.

Drugs 105
article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008. Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

2] However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008. Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed.

article thumbnail

Obstacles and innovations of macrocyclic drug development

Drug Target Review

Phase III trials for MK-0616 commenced in the second half of 2023. Nature Reviews Drug Discovery , 7(7):608624, 2008. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. Cyclic Peptide Design, Chapter 2: Strategies to Enhance Metabolic Stabilities. 8 Why are there not more macrocyclic drugs?